These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors. El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458 [TBL] [Abstract][Full Text] [Related]
23. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053 [TBL] [Abstract][Full Text] [Related]
25. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975 [TBL] [Abstract][Full Text] [Related]
26. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477 [TBL] [Abstract][Full Text] [Related]
27. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers. Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130 [TBL] [Abstract][Full Text] [Related]
28. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739 [TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100278. PubMed ID: 34596910 [TBL] [Abstract][Full Text] [Related]
30. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. Shi L; Wu TT; Wang Z; Xue JY; Xu YG Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347 [TBL] [Abstract][Full Text] [Related]
31. Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors. Atta-Allah SR; AboulMagd AM; Farag PS Bioorg Chem; 2021 Jul; 112():104923. PubMed ID: 33932767 [TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176 [TBL] [Abstract][Full Text] [Related]
33. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity. Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649 [TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer. Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents. Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750 [TBL] [Abstract][Full Text] [Related]
36. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors. Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490 [TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
38. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]